Emricasanum
Emricasanum Uses, Dosage, Side Effects, Food Interaction and all others data.
Emricasanum is the first caspase inhibitor tested in human which has received orphan drug status by FDA. It is developed by Pfizer and made in such a way that it protects liver cells from excessive apoptosis.
| Trade Name | Emricasanum |
| Generic | Emricasan |
| Emricasan Other Names | Emricasan, Emricasán, Emricasanum |
| Type | |
| Formula | C26H27F4N3O7 |
| Weight | Average: 569.51 Monoisotopic: 569.178512873 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Investigated for use/treatment in hepatitis (viral, C), liver disease, and transplantation (organ or tissue).
How Emricasanum works
IDN-6556 significantly improves markers of liver damage in patients infected with the Hepatitis C virus (HCV), an infection that affects up to 170m patients worldwide. IDN-6556 represents a new class of drugs that protect the liver from inflammation and cellular damage induced by viral infections and other causes. Various studies have also shown that it significantly lowers aminotransferase activity in HCV patients and appeared to be well tolerated.
Innovators Monograph
You find simplified version here Emricasanum
